Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7926711 | 0.78 | KIF11 (0.34) | KIF11NOTUM | |
| SCHEMBL13990216 | 0.75 | HTR3E (0.41) | NOTUMAR | |
| SCHEMBL13199169 | 0.74 | AR (0.38) | KIF11TAS2R14NOTUMAR | |
| SCHEMBL27379121 | 0.73 | TAS2R14 (0.41) | TAS2R14NOTUMCFTR | |
| SCHEMBL30755336 | 0.73 | TAS2R14 (0.41) | TAS2R14NOTUMCFTR | |
| SCHEMBL25037002 | 0.72 | PDE2A (0.35) | KIF11NOTUM | |
| SCHEMBL7525298 | 0.70 | TYR (0.39) | TTR | |
| SCHEMBL813488 | 0.70 | TRPA1 (0.39) | TTR | |
| SCHEMBL1603128 | 0.70 | CA2 (0.39) | KIF11NOTUM | |
| SCHEMBL2276181 | 0.70 | TAS2R14 (0.40) | KIF11TAS2R14NOTUMAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NOD1 | KIF11 4535/4885TAS2R14 4286/4885NOTUM 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.